Can you take Amphotericin b with Paracetamol?

The acetaminophen in Paracetamol has a major potential interaction with Alcoholism.

Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP). Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day. In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure. They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.

amphotericin B has a moderate potential interaction with Anemia.

Intravenous amphotericin B therapy may depress erythropoietin and red blood cell production and commonly causes a normocytic, normochromic anemia. Although the anemia is well tolerated by most patients and usually reverses completely within several months of stopping therapy, it may be problematic in patients with preexisting anemia. Intravenous therapy with amphotericin B should be administered cautiously in anemic patients or those predisposed to anemia. Frequent monitoring of blood counts and hemoglobin concentrations are recommended.

The acetaminophen in Paracetamol has a major potential interaction with Dehydration.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

amphotericin B has a moderate potential interaction with Electrolyte Abnormalities.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause hypo- or hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be closely monitored in all patients receiving intravenous therapy with amphotericin B, but in particular, those with preexisting renal and/or electrolyte abnormalities. Mineral and electrolyte supplementation is frequently required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances. Amphotericin B-related electrolyte abnormalities generally improve following cessation of therapy but may persist long after because of the drug's long terminal elimination half-life.

amphotericin B has a moderate potential interaction with Hyperkalemia.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause hypo- or hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be closely monitored in all patients receiving intravenous therapy with amphotericin B, but in particular, those with preexisting renal and/or electrolyte abnormalities. Mineral and electrolyte supplementation is frequently required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances. Amphotericin B-related electrolyte abnormalities generally improve following cessation of therapy but may persist long after because of the drug's long terminal elimination half-life.

amphotericin B has a moderate potential interaction with Hypocalcemia.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause hypo- or hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be closely monitored in all patients receiving intravenous therapy with amphotericin B, but in particular, those with preexisting renal and/or electrolyte abnormalities. Mineral and electrolyte supplementation is frequently required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances. Amphotericin B-related electrolyte abnormalities generally improve following cessation of therapy but may persist long after because of the drug's long terminal elimination half-life.

amphotericin B has a moderate potential interaction with Hypokalemia.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause hypo- or hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be closely monitored in all patients receiving intravenous therapy with amphotericin B, but in particular, those with preexisting renal and/or electrolyte abnormalities. Mineral and electrolyte supplementation is frequently required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances. Amphotericin B-related electrolyte abnormalities generally improve following cessation of therapy but may persist long after because of the drug's long terminal elimination half-life.

The acetaminophen in Paracetamol has a major potential interaction with Liver Disease.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

amphotericin B has a moderate potential interaction with Magnesium Imbalance.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause hypo- or hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be closely monitored in all patients receiving intravenous therapy with amphotericin B, but in particular, those with preexisting renal and/or electrolyte abnormalities. Mineral and electrolyte supplementation is frequently required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances. Amphotericin B-related electrolyte abnormalities generally improve following cessation of therapy but may persist long after because of the drug's long terminal elimination half-life.

The acetaminophen in Paracetamol has a major potential interaction with Malnourishment.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

The acetaminophen in Paracetamol has a moderate potential interaction with Phenylketonuria.

Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet). Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion. Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine. The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

amphotericin B has a moderate potential interaction with Renal Dysfunction.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause decreased renal function and abnormalities including azotemia, hypo- and hyperkalemia, hypomagnesemia, hyposthenuria, renal tubular acidosis, and nephrocalcinosis. Renal function should be closely monitored in all patients receiving intravenous therapy with amphotericin B but in particular, patients with preexisting renal impairment. Dosage reductions are recommended. Serum creatinine, BUN, potassium and magnesium levels should be evaluated frequently, and dosing adjusted or discontinued accordingly.